secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001140361-23-059159
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value
--------------------------------------------------------------------------------

- Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.
- Karuna's lead asset KarXT for schizophrenia; PDUFA date Sept 26, 2024; also in trials for Alzheimer's psychosis.
- Expected to close H1 2024, subject to Karuna shareholder and regulatory approvals; financed with new debt.
- Non-GAAP EPS dilutive by ~$0.30 in 2024 due to financing cost; BMS cites portfolio prioritization to offset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/0001140361-23-059159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/ef20017313_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-059159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer